Company performance
Current Price
as of Jan 20, 2025$1.56
P/E Ratio
N/A
Market Cap
$114.38M
- PVT
Description
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Metrics
Overview
- HQParis, IF
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerALCLS
- Price$1.560455-1.65%
Trading Information
- Market cap$114.38M
- Float71.42%
- Average Daily Volume (1m)90,473
- Average Daily Volume (3m)59,863
- EPS-$0.95
Company
- Revenue$26.67M
- Rev growth (1yr)10,249.73%
- Net income-$20.99M
- Gross margin70.86%
- EBITDA margin-49.85%
- EBITDA-$7.35M
- EV$60.83M
- EV/Revenue2.28
- P/EN/A
- P/S5.68
- P/B1.31
Documents
Factset Street Account
Factset